Early lipid lowering critical in secondary prevention: study

Cardiologist says new evidence is ‘incredibly encouraging’
Sponsored
2
26 October 2020
Save
warrick bishop

This content has been independently produced by ADG, made possible through sponsorship from Amgen

The results of a US study that show rapid LDL-C lowering within one day in patients who were given the PCSK9 inhibitor, evolocumab shortly after a heart attack “may reframe what we are able to do with our patients”, according to an Australian cardiologist.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .